1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCIRM's RAPID program (Rare Disease Accelerated Protein-based Intervention Development) is sponsored by California Institute for Regenerative Medicine (CIRM). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Preclinical Research – CIRM The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. RAPID Awards: Accelerating the Development of Genetic Therapies for Patients with Rare Diseases The RAPID application period opens in July and closes in September 2026.
The Rare Disease Acceleration Through Platform Innovation and Delivery (RAPID) program advances the development and delivery of platform-based genetic therapies for Americans with rare diseases. Download the RAPID Program Request for Applications (RFA) for more details regarding award eligibility, review criteria, and application information.
RAPID Request for Applications [PDF | July 1, 2026] Visit the RAPID Awards page for more information about the RAPID awards, including deadlines, requirements, and FAQs. PDEV Awards: Accelerating Therapies to the Clinic The PDEV application opens in July/August 2026.
The Preclinical Development (PDEV) program supports preclinical development of stem cell-based and genetic therapies that not only offer potential for transformative clinical impact but also meaningfully address current barriers to patient access. Download the PDEV Program Announcement (PA) for more details regarding award eligibility, review criteria, and application information.
PDEV: Program Announcement [PDF | Updated July 1, 2026] Visit the PDEV Awards page for more information about the PDEV awards, including deadlines, requirements, and FAQs. To Submit an Application: 1. Go to the Grants Management Portal 2.
After logging in, click on the Menu tab Select the tab labeled “Open Programs” under the section labeled “RFAs and Programs Open for Applications,” click on the “ Start a Grant Application ” link for your selected program. 3. Complete each section of the Application Click on the appropriate link and follow the posted instructions.
Proposal templates can be located and submitted under the “ Uploads ” section. 4. To submit your Application Click on the “ Done with Application ” button.
The “ Done with Application ” button will be enabled when all the mandatory sections have been completed. Please note that once this has been selected, you will no longer be able to make changes to your application. 5.
To confirm submission of your Application Select the tab labeled “ Your Applications ” and check the table under the section labeled “ Your Submitted Applications. ” You will see your application number and project title listed once the submission process has been completed.
According to the current listing, eligibility includes: Proposals that will advance multiple in vivo genetic therapies to patients with rare diseases. Validation awards will support projects that have already received FDA pre-IND feedback. Confirm the full requirements in the official notice before applying.
The current listing shows $100 million over two years (total program funding). Verify award ceilings, matching requirements, and allowable costs in the official notice.
CIRM's RAPID program (Rare Disease Accelerated Protein-based Intervention Development) is funded by California Institute for Regenerative Medicine (CIRM). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Preclinical Development (PDEV) program is sponsored by California Institute for Regenerative Medicine (CIRM). The PDEV program supports preclinical development of stem cell-based and genetic therapies that offer potential for transformative clinical impact and address current barriers to patient access. This includes research on stem cell-derived retinal pigment epithelium (RPE) cells for treating maculopathies and supporting photoreceptors.
CLIN2 Awards: Funding Opportunity for Clinical Trials is sponsored by California Institute for Regenerative Medicine (CIRM). CIRM's CLIN2 Awards program supports the clinical development of stem cell-based and genetic therapy approaches for treating diseases with unmet medical needs. The program aims to expedite clinical development towards late-stage trials through innovative trial designs and strategies for market access and pre-commercialization.
DARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleThe FY2026 MEP Center State Competition ran in two rounds: eight states worth $139.1 million, then fourteen more worth $232.4 million, both closing August 21, 2026. That's 43 percent of the national network recompeted in twelve months, under a 50 percent non-federal cost share, while the administration's own budget request proposed eliminating the program. Here's what the award tables reveal, why incumbents are genuinely at risk, and how to position for the FY2027 wave.
Read articleOn August 14, 2026, the California Arts Council approved nearly $24.6 million across 1,200 grant awards. Buried in the release is a rare thing: before-and-after data showing exactly how much the ranked-priority bonus moved the pool. Small organizations went from 53% of applicants to 72% of awardees. Geography moved 19 points. First-time status barely moved at all. Here is what that means for the 2027 cycle.
Read article